van Hootegem S J M, Chmelo J, van der Sluis P C, Lagarde S M, Phillips A W, Wijnhoven B P L
Department of Surgery, Erasmus MC University, Rotterdam, the Netherlands.
Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK.
Eur J Surg Oncol. 2024 Apr;50(4):108233. doi: 10.1016/j.ejso.2024.108233. Epub 2024 Feb 27.
Diagnostic laparoscopy (DL) with peritoneal lavage has been adopted as a standard staging procedure for patients with gastric cancer (GC). Evaluation of the value of DL is important given ongoing improvements in diagnostic imaging and treatment. As contemporary data from European centres are sparse, this retrospective cohort study aimed to assess the yield of DL in patients with potentially curable gastric cancer, and to identify predictive factors for peritoneal metastases.
Patients with adenocarcinoma of the stomach, treated between January 2016 and December 2018, were identified from institutional databases of two high volume European Upper-GI centres. Patients who underwent a DL with peritoneal lavage for potentially curable disease after clinical staging with imaging (cT1-4N0-3M0) were included. The primary outcome was the proportion of patients with a positive DL, defined as macroscopic metastatic disease, positive peritoneal cytology washings (PC+) or locally irresectable disease.
Some 80 of 327 included patients (24.5%) had a positive DL, excluding these patients from neoadjuvant treatment (66 of 327; 20.2%) and/or surgical resection (76 of 327; 23.2%). In 34 of 327 patients (10.3%), macroscopic metastatic disease was seen, with peritoneal deposits in 30 of these patients. Only 16 of 30 patients with peritoneal disease had positive cytology. Some 41 of 327 patients (12.5%) that underwent DL had PC+ in the absence of macroscopic metastases and five patients (1.5%) had an irresectable primary tumour. Diffuse type carcinoma had the highest risk of peritoneal dissemination, irrespective of cT and cN categories.
The diagnostic yield of staging laparoscopy is high, changing the management in approximately one quarter of patients. DL should be considered in patients with diffuse type carcinoma irrespective of cT and cN categories.
诊断性腹腔镜检查(DL)联合腹腔灌洗已被用作胃癌(GC)患者的标准分期程序。鉴于诊断成像和治疗方面的不断进步,评估DL的价值很重要。由于欧洲中心的当代数据稀少,这项回顾性队列研究旨在评估DL在潜在可治愈胃癌患者中的诊断率,并确定腹膜转移的预测因素。
从两个欧洲大型上消化道中心的机构数据库中识别出2016年1月至2018年12月期间接受治疗的胃腺癌患者。纳入在影像学临床分期(cT1 - 4N0 - 3M0)后因潜在可治愈疾病接受DL联合腹腔灌洗的患者。主要结局是DL阳性患者的比例,定义为肉眼可见的转移性疾病、腹腔细胞学冲洗阳性(PC +)或局部不可切除的疾病。
327例纳入患者中约80例(24.5%)DL阳性,这些患者被排除在新辅助治疗(327例中的66例;20.2%)和/或手术切除(327例中的76例;23.2%)之外。327例患者中有34例(10.3%)可见肉眼可见的转移性疾病,其中30例有腹膜种植。30例腹膜疾病患者中只有16例细胞学阳性。327例接受DL的患者中有41例(12.5%)在无肉眼可见转移的情况下PC +,5例(1.5%)有不可切除的原发性肿瘤。无论cT和cN分类如何,弥漫型癌腹膜播散风险最高。
分期腹腔镜检查的诊断率很高,约四分之一患者的治疗方案因此改变。无论cT和cN分类如何,弥漫型癌患者均应考虑行DL。